Elon Musk's Neuralink said its experimental Blindsight implant to restore vision received the US Food and Drug Administration's "breakthrough device" designation.
The CellKey® 384 System is a universal, high throughput label-free platform for real-time cell-based functional analysis of endogenous and recombinant receptors. The system enables the ...